Integral Diagnostics Limited (ASX:IDX)
Australia flag Australia · Delayed Price · Currency is AUD
1.620
-0.030 (-1.82%)
Nov 17, 2026, 11:20 AM AEDT
← View all transcripts

AGM 2026

Oct 28, 2026

Summary

FY 2026 delivered higher revenue, EBITDA and dividends, while Q1 FY 2027 was softer amid workforce constraints and uneven execution. Management expects FY 2027 revenue growth of 4%-6% and H2 margin improvement through cost discipline and technology initiatives.

Toby Hall
Chair, Integral Diagnostics

Morning, welcome everybody. I'm Toby Hall, the Chair of Integral Diagnostics, and very pleased to welcome you to our 2026 Annual General Meeting. For those of you in the room, could you please all just check your mobile phones are switched to silent, and also ask you just to note where your nearest exit is in the unlikely event that there's a need to evacuate the building. In the event of any emergency, just follow staff instructions. It is 10:00 A.M., and I'd like to begin by acknowledging the traditional owners and custodians of the land on which we meet today, the Wurundjeri people of the Kulin Nation. I pay my respects to their elders past and present. I've been advised that a quorum is present for the meeting, and therefore declare the meeting open.

Today's meeting is being held in person and virtually by the Computershare platform, where shareholders and proxies can watch a live webcast of the meeting, ask questions, and submit votes. To provide you with sufficient time to vote, I now declare the voting open on all items of business. I will start today's agenda by taking you through a few procedural steps for voting and submitting questions. I will then give an address, and that will be followed by an address from our new Managing Director and Chief Executive Officer, Jason Martinez. I'll now turn to the formal business for the meeting. Firstly, I'd like to introduce my fellow directors who are here with us today, Jason Martinez, at his first meeting, Andrew Fay, Ingrid Player, Laura McBain, Kevin Shaw, and Manish Mittal. Also right at the end is Jenny, who's our new CFO.

Our auditor is present, represented by our lead engagement partner, Amanda Campbell. She's present and very keen to answer any questions related to the conduct of the audit and the auditor's report. Assisting us today is John Merity, our Company Secretary. Several members of our management team are in the room today, and we're happy to talk to you after the meeting. For online attendees, voting today will be conducted by way of poll on all items of business, and Computershare will act as an independent returning officer. For those attending in person, I'll ask you to vote once we've gone through all the items of business today by completing a blue voting card, which was provided to you on admission to the room. White cards are for visitors only who cannot vote or ask questions today.

Shareholders with a yellow card are not entitled to vote on the items of business. For those attending the meeting online who are eligible to vote, a voting icon is available for you on your screen. Selecting this item will bring up a list of resolutions to present you with voting options. It's my duty as Chair to ensure shareholders and proxies have a reasonable opportunity to ask questions and discuss items of business during the meeting. I will take questions once the formal business items have been presented. So far as we can, general questions which don't relate to the resolutions before the meeting will be addressed after the items of formal business. For those in the room, only participants who have been given a blue or yellow voting card are entitled to ask questions.

For those attending the meeting online, you may submit a written question at any time via the Q&A speech bubble on your screen. You can also ask a verbal question by following the questions below the broadcast window on your screen. If you are asking a question, please state your full name before asking your question. Very pleased to be addressing you today. Integral Diagnostics is a healthcare company built on excellent foundations and values. Our services dramatically improve the diagnosis and treatment of illness and injury in the communities in which we operate. Our doctors and employees are motivated, committed, and I am proud to be leading IDX into its next chapter of growth. in FY 2026, IDX continued to improve its financial results year-on-year. Revenue was up 25.6% to AUD 788.7 million. Operating EBITDA was up 30.3% to AUD 164.8 million.

Operating EBITDA margin was up 80 basis points to 20.9%. Operating NPAT was up 50.2% to AUD 47.4 million. Statutory NPAT was up over 600% to AUD 22.0 million. Operating diluted EPS was up 23.6% to AUD 0.126 per share. Total dividends for the year were AUD 0.093, up from AUD 0.065 declared in the preceding financial year. In the context of these strong results, I'd like to emphasize two aspects of our industry. Diagnostic imaging benefits from several long-term tailwinds. Aging population, earlier disease detection, rising chronic disease prevalence, Medicare funding and indexation, MRI deregulation, the recent National Lung Cancer Screening Program, and continuing advancement in AI and teleradiology.

Together, these factors support sustained growth in demand for diagnostic imaging services and reinforce the important role that this sector plays in the Australian healthcare system. But while demand per imaging remains strong, the industry's principal capacity constraint is actually access to skilled clinical professionals. The shortage of radiologists and sonographers across Australia continues to limit the speed at which additional patient demand can be serviced, despite the ongoing investment in technology and infrastructure. We're responding to this through a combination of recruitment, workforce development, training partnerships, and productivity initiatives. But the reality is, developing highly qualified imaging specialists takes time. We therefore expect workforce availability to remain an important focus for both our company and the broader healthcare system for the foreseeable future.

I would also like to acknowledge that notwithstanding our results, our share price has not performed as the board would have hoped over the last 12 months. While some of this share price underperformance can be explained by broader falls across the Australian healthcare stock prices generally over the last 12 months, the current share price is clearly a focus for your board. Our management team has a clear plan and the board's support to drive strategic and operational changes in the current financial year, which the board believes will result in significant benefits in future years. We expect that these changes should be reflected in an improved share price over time. The shareholders would expect the board maintains an active succession plan for key leadership positions and would normally seek to stagger senior executive transitions wherever possible.

The near-simultaneous commencement of our new CEO, Jason Martinez, and CFO, Jenny Martin, in August was therefore not necessarily the board's preferred outcome and arose from circumstances beyond the board's control. Jason was recruited in November 2025 but restrained from commencing until August this year. Jenny, who is the standout candidate in our recruitment process following Craig White's decision to retire earlier this year, was available much earlier than we had anticipated. That said, the true test of succession planning is not whether circumstances unfold exactly as anticipated, but how effectively the organization responds when they do. in this regard, the transition has been handled extremely well. Strong planning, thorough handovers, and a constructive process from all parties has ensured continuity of leadership and execution.

The board has been impressed with the insights of our new executives into our business, how quickly the team has established itself while maintaining a focus on the company's strategic and operational priorities. I would like at this point to express the board's gratitude to our former leadership team of Dr. Ian Kadish and Mr. Craig White for the instrumental role they played in building IDX to its current national position and for facilitating a smooth transition process. I would like also to say a brief word on sustainability. This year we issued our first AASB S2 climate statement. Whilst the reporting requirements are new, the underlying objective isn't. Understanding the risks, opportunities that may affect the company's long-term performance and communicating those to shareholders is clearly our duty.

I am pleased to report IDX has now procured green renewable electricity for 100% of our anticipated Australian electricity consumption over the next three years, contributing to a 93% reduction in our Scope One and market-based Scope Two emissions. Looking ahead, we remain focused on strengthening our climate reporting, identifying practical opportunities to reduce emissions, and strengthening our climate resilience. Finally, in March this year, Raelene Murphy, our Audit Committee Chair, resigned after nine years on the board. On behalf of the board, I would like to thank Raelene for her immense contribution, service and leadership at IDX. Laura McBain has capably stepped into the role of Audit Committee Chair. Finally, I would like to take this opportunity to thank my fellow Directors, IDX's leadership team, and our clinicians and support staff, and you, our fellow shareholders, for your continuing support.

I will now hand over to our brand new managing director.

Jason Martinez
Managing Director and CEO, Integral Diagnostics

Thank you, Toby, and good morning to everyone in the room and online. Yes, this is my first AGM as Managing Director and CEO of IDX. I have been in the role for just under three months, and I want to use this morning to do three things: share my initial observations, explain the tangible actions already underway, and be clear about what you expect from us at the half and full year. I will also be direct about the first quarter. Revenue was softer than expected, and our outlook reflects that. But the key takeaway this morning is that our margin improves in the second half, because that is what the team controls, and most directly, I will run through the tangible steps today to get us there. Before I do this, I would like to acknowledge Dr. Ian Kadish.

Over eight years, Ian took IDX from a regional radiology practice to one of the largest networks in Australia and New Zealand, and he completed the merger with Capitol Health. I inherited a business with real scale, strong clinical standards, and a team who cares about getting it right for patients. That is a very good place to start. I would like to also thank Craig White, who retired as CFO after the FY 2026 result, and welcome Jenny Martin, who joins us as the Chief Financial Officer this month. Let me start with how we plan to engage with you throughout the year. Today, I will share my observations after three months, the actions already underway, the industry context, our Q1 trading update, and FY 2027 outlook.

At the half year, we will quantify annualized run- rate benefits and delivery costs separately, report financial and non-financial operating metrics, explain margin and earning movements, including one-off and timing items. We will update you on New Zealand's strategic review and provide progress on our overall strategy execution. In August, we will present the medium and long-term strategy outlook, multi-year performance measures, growth pathways, and capital allocation framework. That sequencing is deliberate. Three months is enough time to assess the fundamentals, identify the most important opportunities, and begin acting. We will explain what we are doing now, report progress at the half year, and in August, provide a broader update on strategy execution and our long-term ambitions. Diagnostic imaging sits at the front of most diagnosis and treatment pathways. Demand is driven by aging, chronic disease, and early detection.

The sector is predominantly Medicare-funded, with annual indexation of 2.4% in FY 2026 and 2.6% in FY 2027, excluding PET nuclear imaging services. Growth is also moving towards higher-end modalities with MRI deregulation, the National Lung Cancer Screening Program, and breast MRI screening, adding funding and demand in PET, MRI, and CT. IDX is well-placed in that market. We are Australia's third- largest provider with 11.9% share, up from 7.1% in 2022. Across Australia and New Zealand, we have 141 clinics, 445 radiologists, plus 144 contracted teleradiologists across our group. We now have 43 MRIs at Australian licensed practices, up from 23 a year earlier. As at 30th September 2026, IDXt accounts for 14.2% of reporting, and AI is applied to approximately 18.2% of scans. In recent years, Medicare benefits for imaging have grown around 7% per year. That is sector context, not a forecast for IDX.

Turning market growth into earnings depends on two things: having clinical capability to meet demand and keeping cost growth below revenue growth. In the first quarter, the business did not achieve either as well as it should have, and that is what we are working to fix. Toby has taken you through the FY 2026 financial results, I will focus on what they mean operationally. Revenue grew 25.6% to AUD 788.7 million, which includes the first full year of Capitol Health. The operating EBITDA margin increased 80 basis points to 20.9%, and we delivered more than AUD 14 million in Capitol Health merger synergies. Those results provide the basis and the base for our next task, capturing the benefits of our scale and more consistently across the group. The operating task now is to build on those results by capturing the benefits of our greater scale more consistently across our group.

That means stronger discipline, more consistent execution, and clear accountability for clinic performance. We continue to invest in clinical network. During the year, we opened new comprehensive clinics at Wangaratta and Eastwood Private Hospital, incorporating new MRI capability. We also relocated and expanded our Launceston clinic to include MRI services. These investments improved access to advanced digital imaging and strengthened our presence in those communities we serve. Most importantly, our performance is measured not only by financial results, but also the care we provide patients and our communities. During FY 2026, we served approximately 1.7 million patients and performed more than 4 million examinations. Patient satisfaction remained exceptionally high, with a Net Promoter Score of +81. This result reflects dedication and professionalism of our radiologists, our clinical teams, and our support staff across Australia and New Zealand. We also maintain strong employee engagement.

We continue to build a more connected and accountable culture and progress investment in technology and systems to improve the experience of both our patients and our people. Overall, FY 2026 demonstrated the strength of our business, the quality of clinical services, and the commitment of our people. Three months in, what have I found? Firstly, the fundamentals are sound. Demand is there. Our referral relationships are healthy, and our clinical quality is high right across our network. Our clinical IT platform with Clario and FIM provide a strong platform to leverage the latest AI and tech. Nothing I have seen in the three months changes the long-term case for this business. Second, performance is uneven by geography. Metro Victoria is the clearest example. It has lagged the rest of the group at both the top and bottom line, and is where we have moved first.

More consistent execution is the immediate priority. Third, labor needs to be forecast and managed, not simply reported after the fact. Doctor cost and rostering have historically been managed retrospectively. In practice, that meant that growth cost was often recognized after it happened rather than planned and managed ahead of time. It is the main reason our costs grew faster than revenue in the first quarter, and this is where we can make the quickest difference. Better forward visibility, disciplined scheduling, and closer alignment between revenue and remuneration are among the first changes underway. Fourthly, we are developing a clear strategy that links work of every IDX team to the company's purpose and priorities. That means aligning our people, resources, and investment to deliver sustainable growth and shareholder value.

The point I want to leave you is this: we have identified concrete operating actions and are working through them now. Workforce shortages remains a constraint, but stronger forecasting, more disciplined scheduling, and consistent execution are areas that we can act. Our job is to compete for radiologists and sonographers where they can improve our service offering, and to use technology to make each one more productive. A refreshed leadership team, including Jenny Martin, our CFO, our new general manager in Victoria from within the industry, supports our work. Revenue grew 3% in Q1, or 4.4% excluding closed sites and adjusting for constant currency. In Australia, revenue growth excluding closed sites was 5.1% against estimated Medicare benefits growth of 7.1% for Q1 FY 2027. To reiterate, the demand for services was there at our clinics in Australia.

Our capacity to meet it was not because we did not have enough radiologists and sonographers in the right places. Metro Victoria sites continued to underperform at both the top and bottom line. We have appointed a new general manager in September with more than 25 years of industry experience, and clinic profitability is the immediate priority. Our South Coast Radiology revenue growth was flat because we had doctor shortages. Across the group, our MRI revenue grew by more than 10%, and we are broadly in line with CT growth in the services we provide, consistent with our focus on high-end modality. Staff shortages reduced ultrasound capacity. Volumes increased in our hospital contracts and the new Maroochy Private Hospital site opened in August, exceeding revenue expectations.

In New Zealand, revenue declined 6.5% in NZD or 15.1% in AUD , with the AUD result also reflecting unfavorable exchange rate movements. 4.5% of the decline in revenue is due to the absence of CT referrals from Health New Zealand, an industry-wide issue, and 2% to our site closure. The strategic review remains underway and will update the market at the half-year results or earlier, if appropriate. Radiologist costs as a percentage of revenue increased in Q1 because of the number of one-off and timing factors. Doctor shortages increased reliance on locums, and additional incentives were paid in July and August to reduce unreported lists. The rollout of Clario in Victoria, our largest region, also had a short-term negative impact on productivity. The removal of quarterly superannuation cap brought 52% of expected annual radiologist superannuation into Q1.

Some of this unwinds within the year because more of the superannuation costs fall in the first quarter, less of it falls in subsequent quarters. These factors weigh on the first half and are not expected to recur at the same level in the second. Following Capitol integration, the group also recharacterized AUD 2.5 million of annualized labor costs from below the line to above the line. This changes how we report the cost, not what we spend, and it gives a clearer view on underlying earnings. It also means our margins from here carry the cost that earlier periods did not. Both labor and other costs grow and are currently outpacing revenue growth, and action to reduce unnecessary costs have commenced. The FY 2027 outlook. Revenue growth in the first quarter was softer than expected, driven by labor shortages.

We expect the full-year FY 2027 revenue growth to be between 4% and 6%. We are taking action to reset the cost base across both labor and non-labor costs with initiatives already underway. Our focus is on stronger operational and cost discipline to improve operating leverage. In parallel, we are accelerating technology initiatives to improve productivity and moving towards a more national coordinated approach to procurement. That assumes growth improves from the first quarter as the clinical appointments we have made come through the new sites, including Maroochy and builds volume. Revenue is only part of the picture. Costs and the resulting margin are what our team controls more directly, and that is where I want to be specific and offer you as much tangible detail as possible. Following implementation of these cost initiatives, we expect our operating EBITDA margins to improve in the second half of FY 2027.

For the full year, we can expect an EBITDA margin in the range of 19.5%-20.5%. The full-year range reflects a first half that carries one-off timing costs that I've described. The second half reflects the cost initiatives, which will have an early impact and which are already underway. Less reliance on locums, more disciplined rostering and procurement and non-labor savings that we've started to capture. It does in part depend on revenue growth, but with enough buffer based on our expectations for business going forward. Our FY 2027 capital expenditure guidance remains at AUD 50 million-AUD 60 million. Our FY 2027 work has three priorities: stronger operating discipline, greater use of our scale, and technology that improves productivity and experience. Operationally, clinic profitability in Victoria is the immediate priority.

Across the group, we are strengthening forecast for doctor costs, matching labor more closely to demand, and competing harder to attract and retain radiologists and sonographers throughout EVP. We are also reviewing pricing by modality and geography, assessing low-margin clinics and our footprint, and linking remuneration more closely to revenue. On scale, we are consolidating and centralizing where that creates value. We are extending centrally negotiated procurement, moving typing workflow and facilities management towards a national model, and establishing more consistent reporting and clear accountabilities across the business units. A unified operating model and culture will help us act as one network and capture the benefits of scale. On technology, the board-approved Prioritizing Access and Customer Experience program, or PACE, as we like to call it, covers online bookings, digital forms, electronic referrals, unified work list, and voice AI.

The Clario rollout is progressing well, creating a shared radiologist reporting environment across the business. Alongside this, we are supporting AI-enabled solutions and looking at autonomous draft reporting to improve reporting turnaround and productivity, and we are extending our IDXt deployment. Together, these initiatives are intended to improve patient and referrer experience and lower the cost to serve over time. We will track digital bookings and referrals, the share of scans with AI applied, and further IDXt deployment. These initiatives are underway or approved. At the half-year results, we will report their benefits and delivery costs separately and explain how they'll support sustainable margin improvement. Beyond these priorities, we are building a disciplined pipeline for the next phase of growth, where we'll use existing capacity first, then assess greenfield and brownfield opportunities, new hospital contracts, and selective M&A.

Each opportunity will be measured against the return we can earn on the capital invested. Our scale, IDXt, and the clinical model provide options for the long term, with future investment guided by our disciplined capital allocation framework. IDX has a strong underlying business, and we know where performance must improve. Our priorities are clear: execute within the platform, pursue disciplined and selective growth, build capability and culture, and use transformation and innovation to improve pathways and productivity. The outcomes we will measure ourselves against are, sustainable revenue growth, EBITDA margin improvement, greater productivity and capacity, improved patient access, and continued balance sheet de-gearing. We are taking tangible actions and are confident in our ability to deliver improved performance and sustainable shareholder returns. The first measure of that will be the second half margin, and we will report our progress towards in February.

I would like to thank our radiologists, sonographers, radiographers, nurses, and support team whose commitment to patients is evident across our network every day. Thank you also to our referrers and patients for their trust, to Toby and to the board, and to the leadership team for their support through my first months, and to you, our shareholders, for your patience and your confidence in the company. Thank you.

Toby Hall
Chair, Integral Diagnostics

Thanks very much for that, Jason. I will now proceed to the formal business as set out in the notice of meeting dated 25th September 2026. a number of shareholders have already voted ahead of the meeting, and we thank them for their insight. I will introduce each resolution in turn, and the proxy results for each resolution will be displayed on the screen. Shareholders will have a chance to ask questions on each resolution before we move on to the next one. The first item of business is to receive and consider the financial report of the company and its controlled entities and the reports of the directors and auditors for the year ended 30th June 2026. This item does not require a vote from shareholders. I will now invite questions on this item. Good. John, no online questions.

There being no further questions, we will come to the items of business for which voting is required. Item two relates to the adoption of the remuneration report. The resolution being put to the meeting is displayed on the screen. The remuneration report is contained in the annual report. It describes the policies and sets out the remuneration arrangements in place for directors and executive key management personnel. The vote on this item is advisory only and does not bind the directors of the company. Nevertheless, the People, Culture, and Remuneration Committee will take into account the discussion on this item and the outcome of the vote when considering the future remuneration policies and practices of the company. The valid proxies for item two are shown on the screen. Are there any questions or comments in relation to this resolution? John, are there any online questions?

As there are no further questions on this resolution, I move that the remuneration report for the year ended 30th June 2026 be adopted. That concludes the business for item two. I will now stand aside and Andy Fay will come and look after this part of the meeting.

Andrew Fay
Independent Non-Executive Director, Integral Diagnostics

Morning, everyone. Item three relates to the re-election of Toby Hall as Director. Toby's qualifications and experience are set out in the notice of the meeting. I will now invite Toby to say a few words on his re-election.

Toby Hall
Chair, Integral Diagnostics

Thanks very much for that, Andy. It is good to be back up here. As I said earlier, it is good to be able to do this more informally. This organization is at the forefront of health services in Australia. I believe that diagnostic imaging is going to be the center of the health sector for the long-term future. We have incredible tailwinds behind this business. The demand and the growth of diagnostic imaging services is quite incredible. The need for it for prevention activity in terms of the healthcare system is absolutely vital. We are very lucky, we have a great technology team. I think we have some of the best AI technology in the business, in the sector. That work allows us to impact Australian lives on a daily basis.

It is a privilege to lead an organization that works with close to 2 million people a year to ensure that their health is as good as it can be. I will continue to serve the shareholders and be a shareholder of the board as long as you invite me to.

Andrew Fay
Independent Non-Executive Director, Integral Diagnostics

Thanks, Toby. I think it's pretty clear his passion for the business and how he goes about it in creating an exciting place, but also very disciplined. The resolution to the meeting is displayed on the screen. The board, with Toby abstaining, we unanimously recommend that the shareholders vote in favor of the resolution. The valid proxies for item three are also shown on the screen. Are there any questions relating to this resolution? Any questions, [John]? Okay, there are no further questions. I put that Toby be eligible, and being eligible, be re-elected as a Director of the company.

Toby Hall
Chair, Integral Diagnostics

Thank you very much, Andy. We'll now move to the re-election of Ingrid Player as Director. Item four relates to the election of Ingrid as a Director. Details of Ingrid's qualifications and experience were set out in notice of meeting. I now invite Ingrid to say a few words regarding her election.

Ingrid Player
Independent Non-Executive Director and Chair of the Risk, Compliance and Sustainability Committee, Integral Diagnostics

Thank you, Toby. Good morning, everybody. My name is Ingrid Player. I have been lucky enough to be a board member for the last three years, and I present myself for re-election again today. I've been an active member of the board and of its committees over the last three years, and I currently Chair the Risk and Sustainability Committee. It's hard to rival Toby's passion for IDX, but we are all equally passionate, although maybe less effusive in our tone. In addition to serving here at IDX, I also serve as a non-executive director at two other ASX-listed companies, Cleanaway, Australia's largest integrated waste management company, and Cogstate which is a cognition testing company supporting global clinical trials. I also work with Epworth Foundation, Victoria's largest nonprofit hospital group.

I bring all that experience with me to IDX, and as Jason mentioned, IDX is a company full of great people. They work hard every day to deliver high-quality diagnostic services and care for our patients, and we see this directly in the work of the Risk and Sustainability Committee. Many of you might not think that risk is the most exciting topic going around, but you'd be very excited to be part of our Risk and Sustainability Committee meetings because that's where we get to see the passion of our people front and center at every meeting. That's where we work on our top risks as an organization, and amongst those include ensuring safe workplaces for our people, and a robust clinical governance system and process for our patients, and that we do all of that sustainably.

You heard from Toby earlier about our purchasing of green power, which some of our leaders are in the room today who are responsible for that deal, and we are thrilled. With your support, I look forward to continuing to serve our shareholders for a further term and to working with our refreshed management team to deliver our sustainable growth and shareholder value. Thank you for your consideration.

Toby Hall
Chair, Integral Diagnostics

Thank you very much, Ingrid. The resolution being put to the meeting is displayed on screen. The board, with Ingrid abstaining, unanimously recommends shareholders vote in favor of the resolution. I would just add she is an excellent contributor to the board and an excellent committee chair. Valid proxies received for item four are shown on the screen. Are there any questions or comments in relation to the resolution? John, any online questions? As there are no further questions on this resolution, I move that Ingrid Player, being eligible, be re-elected as a Director of the company. That concludes the business for item four. There are two resolutions related to approval of equity grants to the CEO. The proposed grant of FY 2027 short-term incentive rights and the FY 2027 long-term incentive rights to our CEO, Jason Martinez.

Details of the terms and conditions of the proposed equity grants are set out in the notice of meeting. The resolution being put to the meeting, sorry to say, are being put to the meeting are displayed on screen. The board, with Jason abstaining, unanimously recommends that shareholders vote in favor of both resolutions. The valid proxies received by the company for items 5(a) and 5(b) are shown on the screen. Are there any questions or comments in relation to this resolution? John, are there any online questions? As there are no further questions to this resolution, I move that approval be given for all purposes for the grant of deferred equity rights to the Chief Executive Officer and Managing Director, Mr. Jason Martinez, under the IDX FY 2027 short-term incentive plan on the terms set out in the explanatory memorandum.

That approval be given for all purposes for the grant of 369,458 performance rights to the Chief Executive Officer and Managing Director, Mr. Jason Martinez, under the IDX FY 2027 long-term incentive plan on the terms set out in the explanatory memorandum. That concludes the business for items 5(a) and 5(b). There are also two resolutions for this item relating to proposed top-up grant of FY 2026 long-term incentive rights and FY 2027 long-term incentive rights to our former CEO, Dr. Ian Kadish. Details of the terms and conditions of the proposed equity grants are set out in the notice of meeting. The resolutions being put to the meeting are displayed on the screen. The board unanimously recommends that shareholders vote in favor of both resolutions. The valid proxies received by the company for items 6(a) and 6(b) are shown on the screen.

Are there any questions or comments in relation to this resolution? John, are there any online questions? As there are no further questions on this resolution, I move that the approval be given for all purposes for the pro rata grant of an additional 71,060 performance rights to Dr. Ian Kadish under the IDX FY 2026 long-term incentive plan on the terms set out in the explanatory memorandum. And that approval be given for all purposes for the pro rata grant of 87,181 performance rights to Dr. Ian Kadish under the IDX FY 2027 long-term incentive plan on the terms set out in the explanatory memorandum. That concludes business for items 6(a) and 6(b). Move on to item seven, approval for issue of securities under the company's equity incentive plan.

This item of business seeks approval for the issue of any securities under the plan, not to count towards the company's 15% annual limit on issuing securities without shareholder approval in the next three years. Details of the proposed resolution are set out in the notice of meeting. The resolution being put to the meeting is displayed on the screen. The board, with Mr. Martinez abstaining, unanimously recommends that shareholders vote in favor of the resolution. The valid proxies received for item seven by the company are shown on the screen. Are there any questions or comments in relation to this resolution? John, are there any online questions? As there are no further questions on this resolution, I move that approval be given for all purposes for issues of securities under the company's equity incentive plan on the terms set out in the explanatory memorandum.

That concludes business for item seven. Moving on to item eight, renewal of the proportional takeover approvals, approval provisions in the constitution. This item allows shareholders to decide collectively whether a proportional takeover bid is acceptable in principle, and it may ensure that any partial offer is appropriately priced. Details of the proposed resolution are set out in the notice of meeting. The resolution being put to the meeting is displayed on the screen, and it is a special resolution. The board unanimously recommends that shareholders vote in favor of the resolution. The valid proxies received for item eight by the company are shown on the screen. Are there any questions or comments in relation to this resolution? John, are there any online questions?

As there are no further questions on this resolution, I move that pursuant to Section 648G of the Corporations Act, the existing proportional takeover provisions contained in Rule Six of the company's constitution be renewed for a period of three years from the date of this meeting. That concludes the last item of business. I'll now take general questions relating to IDX from any shareholders, if there are any. First, I'll come to the room. Yes, sir.

George Markou
Shareholder, Private Investor

This is a question for Jason Martinez. I am George Markou, a shareholder. My background is clinical biochemistry and finance. To what extent do you think subleasing part of the 141 centers to a blood collection to bring more patients into the clinics and be aware of the position that our company has got these clinics, and at the same time, you will have a little bit of a revenue from subleasing?

Jason Martinez
Managing Director and CEO, Integral Diagnostics

Thanks for the question. I think when we look at our existing floor plans in the leases that we have, I agree we should maximize the revenue that we currently have. Do you want me to go to the microphones?

George Markou
Shareholder, Private Investor

Microphones, I think.

Jason Martinez
Managing Director and CEO, Integral Diagnostics

Yeah, we will get you a microphone, George. Sorry. Apologies. Sorry, you can now hear me. Thank you for the question. When we look at our current floor space, our mission is to maximize the revenue that we get in the floor spaces that we have. There is a number of clinics where we sublease to consultants, which are typically referrers. I think it is something we can have a look at. It is not probably the most direct linkage around pathology and radiology together. Pathology, sure, it is a diagnostic tool, but it does not typically generate revenue for us. What we like to do is clearly maximize our floor space for diagnostic imaging and provide as much service that we can for the communities where we are located.

Secondary, where we do have excess capacity, we look to lease that space or provide that space to referring clinicians, where we can obviously service them.

Toby Hall
Chair, Integral Diagnostics

Thank you for the question. Are there any further questions from the floor?

Mark Tobey
Shareholder, Private Investor

Chair. Second.

Sure. Yes, Chair, Mark Tobey, a shareholder. Thanks for your comments about the shareholder, and the share price, but I guess it wasn't a good start today. My question, to Jason is, with your background there in the sector and perhaps more broadly, can you give us a feel of benchmarking where the efficiency of the organization is at? Particularly, if you might reference that to Victoria and give us a better understanding or quantification of where Victoria is relative to where it should be or the industry standard.

Jason Martinez
Managing Director and CEO, Integral Diagnostics

Sure. Yes, I've been in the industry for a very long time and spent 11 years at one of the competitors. So, I know the industry well. I think when you look at our performance, I did call out Victoria Metro clinics. Our opportunity as an organization is we have demand we just aren't currently filling. So I talk about our focus in labor, and it's twofold. It's one, making sure that we match our current labor to the volumes coming in. And importantly, we fight and we recruit for radiologists and sonographers to meet that unmet demand. So that's absolutely our priority at the moment.

Mark Tobey
Shareholder, Private Investor

If I could just do a follow-up. Does that mean that labor's being bid up? Is the price being bid up? If it's a market where the cost of labor is being bid up, and by the old with how, what does that mean in terms of being able to manage that cost line?

Jason Martinez
Managing Director and CEO, Integral Diagnostics

Yeah, so labor is scarce, particularly with radiologists and for sonographers. It's about the market and radiologists and sonographers in particular, being completely aware about our EVP, what we offer. It's not always about the money. Healthcare, it's not always about the money. It's about working conditions, about clinical independence. We need to be able to compete and attract people, and importantly, retain people in doing that. It's not always about price.

Toby Hall
Chair, Integral Diagnostics

Any further questions from the floor? John, are there any online questions? As there are no further questions, that concludes our discussions for today. Shortly, I will close the online voting system. Please ensure that you have cast your vote on all resolutions. I'll now pause to allow time to finalize the votes. Thank you, everyone. Voting is now closed. The voting results for this meeting will be released to the ASX later today. That concludes our meeting. Thank you for taking the time to join the directors and myself today. Your ongoing support as shareholders is greatly appreciated. For those of you in the room, feel free to stay around and come and have a chat with us directors. Thank you very much, everyone.